CEO's On the Move

Taro Pharmaceutical Industries Ltd. Appoints Abhay Gandhi as Interim Ceo, Effective January 1, 2017
12/1/2016
Taro Pharmaceutical Industries Ltd. (TARO:US:NYSE) Taro Pharmaceutical Industries Ltd. announced that its Board of Directors has appointed Mr. Abhay Gandhi to the position of Interim Chief Executive Officer, effective January 1, 2017. As previously announced, the Interim CEO will serve in this role during the period from Mr. Kal Sundaram’s departure ...

Upcoming Board Meetings

Alpargatas S.A.
(874525:Sao Paulo Stock Exchange)
December 2, 2016
Alpargatas S.A., Board Meeting, Dec 02, 2016. Agenda: To Consider Approval of Operational Plan 2017.
Announced 12/14/15
Alpargatas S.A. Key Board Members
Vincent Trius
Chairman of the Board
José da Silva Filho
Chairman of the Board of Statutory Auditors

Executive Changes

Finbar Group Limited Announces Management Changes
12/2/16
Finbar Group Limited announced that the appointment of Edward Bank as company Secretary to the Group and its subsidiaries. Edward (Ed) Bank has served as Chief Financial Officer since 2005 and was previously company Secretary of the group between 2010 and 2013. The company's outgoing Company Secretary, is Mr. Anthony Hewett.
Alto Metals Limited Announces Board Changes
12/2/16
Alto Metals Limited announced the appointment of Mr. Terry Wheeler as non-executive director of the company, and the resignation of Mr. William (Bill) Robertson. Mr. Robertson has resigned from his non-executive director role at company to focus on his geophysical constancy, Value Adding Resources Pty Ltd. Mr. Robertson played an integral role in establishing Alto Metals as a listed company in late 2012, and will continue to consult to Alto in his area of expertise.
BNN Technology plc Announces Retirement of Robert Lerwill as Non-Executive Director
12/2/16
BNN Technology plc announced that Robert Lerwill has retired from his position as Non-Executive Director for personal reasons. Robert joined the Board in May 2014, prior to the Company's IPO, and has overseen significant changes at BNN Technology.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Top Compensated Executives at TARO:US

Name/TitleAnnual Compensation
Kalyanasundaram Subramanian$800.0K
Chief Executive Officer and Director
Michael Perfetto$690.6K
Group Vice President and Chief Commercial Officer of the Generic Rx Business, U.S.A.
Compensation as of Fiscal Year 2015. All Compensation is in USD.

Average Compensation in the Pharmaceuticals Industry

Pharmaceuticals
$579.2K
Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.